Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,581 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all
Not listed Phase 1 Interventional

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

NCT00710697
View directory record Official record
Conditions
Solid Tumors
Interventions
Picoplatin
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 21, 2026, 7:38 AM EDT
Recruiting Phase 2 Interventional

Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)

NCT07762586
View directory record Official record
Conditions
Bladder Cancer
Interventions
Neoadjuvant Therapy, Upfront radical cystectomy
Drug · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

NCT00003342
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, carboplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 21, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

NCT02316548
View directory record Official record
Conditions
Stage III Bladder Cancer, Stage IV Bladder Cancer
Interventions
Intensity-Modulated Radiation Therapy
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
116
States / cities
Bakersfield, California • Greenbrae, California • Los Angeles, California + 97 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

NCT04534491
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin (Oxytrol, BAY839380)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 21, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

NCT00358397
View directory record Official record
Conditions
Tumors
Interventions
Clostridium novyi-NT spores
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 21, 2026, 7:38 AM EDT
Recruiting No phase listed Observational

Evaluation for NCI Surgery Branch Clinical Research Protocols

NCT00001823
View directory record Official record
Conditions
Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Withdrawn Not applicable Interventional

Study of Endoscopic Versus Open Surgery for Urinary Reflux

NCT00830479
View directory record Official record
Conditions
Vesicoureteral Reflux
Interventions
Anti-reflux surgery, Endoscopic injection
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Not applicable Interventional Results available

Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention

NCT04236596
View directory record Official record
Conditions
Urinary Retention, Underactive Bladder
Interventions
Participants received a Neurostimulator, which was used to map the pudendal nerve
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

NCT01162785
View directory record Official record
Conditions
Bladder Cancer
Interventions
SCH 721015
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 21, 2026, 7:38 AM EDT
Active, not recruiting No phase listed Observational

Tempus Priority Study: A Pan-tumor Observational Study

NCT05179824
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

NCT02262455
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
Interventions
STM 434, Liposomal doxorubicin
Drug
Lead sponsor
Santa Maria Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Not applicable Interventional

Connected Catheter Clinical Feasibility Study( CFS)

NCT03405285
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Connected Catheter
Device
Lead sponsor
Spinal Singularity
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Downey, California • Murrieta, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 21, 2026, 7:38 AM EDT
Terminated No phase listed Observational

Biomarker Identification for Bladder Cancer Patients

NCT02053662
View directory record Official record
Conditions
Bladder Cancer
Interventions
Sample Collection
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 21, 2026, 7:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bladder Cancer Case Control Study of Arsenic in Water

NCT00011518
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
20 Years to 85 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2006 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TEST-ON - Does iStim Reduce Urinary Urgency?

NCT04957524
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions
iStim TENS unit and Transvaginal Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

NCT02643303
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Durvalumab, Tremelimumab, Poly-ICLC
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 21, 2026, 7:38 AM EDT
Recruiting No phase listed Observational

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

NCT07225127
View directory record Official record
Conditions
Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Tampa, Florida • Iowa City, Iowa • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Durvalumab, Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Goodyear, Arizona • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05375903
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
Interventions
UGN-301, UGN-201, Gemcitabine
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 7:38 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Susceptibility to Bladder Cancer

NCT00848289
View directory record Official record
Conditions
Bladder Cancer
Interventions
Interviews
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
6,086 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 7:38 AM EDT